{
    "nctId": "NCT00296010",
    "briefTitle": "Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer",
    "officialTitle": "Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx, Doxil) for Women (Age 66 Years or Older) With Endocrine Nonresponsive Breast Cancer Who Are Not Suitable for Being Offered a \" Standard Chemotherapy Regimen\"",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 77,
    "primaryOutcomeMeasure": "Breast cancer free interval by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Disease must be confined to the breast and axillary nodes without detected masses elsewhere\n  * No history of prior ipsilateral or contralateral invasive breast cancer\n* Resected disease\n\n  * No more than 16 weeks since last surgery to remove the tumor\n  * No known clinical residual locoregional disease\n  * Margins must be negative for invasive breast cancer and ductal carcinoma in situ\n* No locally advanced, inoperable breast cancer including any of the following:\n\n  * Inflammatory breast cancer\n  * Supraclavicular node involvement\n  * Enlarged internal mammary nodes unless pathologically negative\n* Synchronous bilateral invasive breast cancer (diagnosed in the past 2 months) allowed if all tumors are hormone receptor-negative\n* Must not be a candidate for endocrine therapy or standard chemotherapy\n* Hormone receptor-negative disease\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Menopausal status: postmenopausal\n* ECOG performance status 0-2\n* Platelet count \u2265 100,000/mm\\^3\n* Granulocyte count \u2265 1,500/mm\\^3\n* WBC \u2265 3,000/mm\\^3\n* AST and ALT \u2264 1.5 times upper limit of normal (ULN)\n* Bilirubin normal\n* Creatinine clearance \u2265 50 mL/min\n* Creatinine \\< 1.35 mg/dL\n* No significant malabsorption syndrome or disease affecting gastrointestinal tract function\n* No myocardial infarction within the past 6 months\n* No pulmonary embolism within the past 6 months\n* No deep vein thrombosis within the past 6 months\n* No New York Heart Association class III or IV heart disease\n* LVEF \u2265 50% by echocardiography, radionucleotide ventriculography, or MUGA\n* No evidence of acute ischemia by ECG\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or bladder, or ipsilateral or contralateral breast carcinoma in situ\n* No active, uncontrolled infection\n* No active hepatitis B or C virus infection\n* No other chronic infection\n* Patients must not have any of the following \"geriatric syndromes\":\n\n  * Dementia\n  * Delirium\n  * Major depression (as diagnosed by a psychiatrist)\n  * Recent falls\n  * Spontaneous bone fractures\n  * Neglect\n  * Abuse\n* No evidence of medically relevant conduction system abnormalities that would preclude study entry\n* No other nonmalignant, uncontrolled systemic diseases, psychiatric illness, or addictive or cognitive disorder that would preclude study participation or compliance\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 4 weeks since prior raloxifene, tamoxifen citrate, or other selective estrogen receptor modulators (SERMs)\n* No concurrent recombinant human epoetin alfa or pegfilgrastim\n* No prior neoadjuvant or adjuvant therapy for breast cancer except radiotherapy\n* Concurrent trastuzumab (Herceptin\u00ae) allowed\n* No concurrent hormonal replacement therapy\n* No other concurrent hormonal therapy (including estrogen, progesterone, androgens, tamoxifen citrate, SERMs, or aromatase inhibitors) except for the following:\n\n  * Steroids for adrenal failure\n  * Hormones for non-disease-related conditions (e.g., insulin for diabetes)\n  * Intermittent dexamethasone as an antiemetic\n* No other concurrent investigational agents\n* No concurrent bisphosphonates, except for the treatment of osteoporosis\n* For patients who received prior anthracyclines, the following criteria must be met:\n\n  * Cumulative dose \u2264 240 mg/m\u00b2 for conventional doxorubicin\n\n    * \u2264 140 mg/m\u00b2 in case of prior doxorubicin and left chest radiotherapy (LCRT)\n  * Cumulative dose \u2264 400 mg/m\u00b2 for epirubicin\n\n    * \u2264 230 mg/m\u00b2 in case of prior epirubicin and LCRT",
    "sex": "FEMALE",
    "minimumAge": "66 Years",
    "stdAges": "OLDER_ADULT"
}